{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:42:53Z","timestamp":1789504973840,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20RR018757"],"award-info":[{"award-number":["P20RR018757"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1038\/jid.2011.351","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T09:48:36Z","timestamp":1320918516000},"page":"703-710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"P1","title":["High Soluble CD30, CD25, and IL-6 May Identify Patients with Worse Survival in CD30+ Cutaneous Lymphomas and Early Mycosis Fungoides"],"prefix":"10.1016","volume":"132","author":[{"given":"Marshall E.","family":"Kadin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Y.","family":"Pavlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Vonderheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2011.351_bb0010","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2133.2006.07346.x","article-title":"Mycosis fungoides associated with B-cell malignancies","volume":"155","author":"Barzilai","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2011.351_bb0015","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"key":"10.1038\/jid.2011.351_bb0020","first-page":"349","article-title":"CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis","volume":"142","author":"Borchmann","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1038\/jid.2011.351_bb0025","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/jid.2009.299","article-title":"Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP","volume":"130","author":"Braun","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1038\/jid.2011.351_bb0030","first-page":"949","article-title":"From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors","volume":"137","author":"Burg","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1038\/jid.2011.351_bb0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2133.2003.05248.x","article-title":"Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature","volume":"148","author":"Burg","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2011.351_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/nrc2782","article-title":"Systemic inflammation as a confounding factor in cancer biomarker discovery and validation","volume":"10","author":"Chechlinska","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/jid.2011.351_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1096\/fasebj.9.1.7821763","article-title":"Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines","volume":"9","author":"Del Prete","year":"1995","journal-title":"FASEB J"},{"key":"10.1038\/jid.2011.351_bb0050","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","article-title":"CD30 expression and proliferative fraction in nontransformed mycosis fungoides","volume":"33","author":"Edinger","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/jid.2011.351_bb0055","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archderm.140.4.441","article-title":"Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C","volume":"140","author":"El Shabrawi-Caelen","year":"2004","journal-title":"Arch Dermatol"},{"issue":"Suppl 4","key":"10.1038\/jid.2011.351_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/3.suppl_4.S49","article-title":"Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma","volume":"3","author":"Gause","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1038\/jid.2011.351_bb0065","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1634\/theoncologist.11-8-955","article-title":"Prognosis of lymphomatoid papulosis","volume":"11","author":"Gruber","year":"2006","journal-title":"Oncologist"},{"key":"10.1038\/jid.2011.351_bb0070","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00277-007-0276-8","article-title":"High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage","volume":"86","author":"Hallermann","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1038\/jid.2011.351_bb0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jaad.2009.03.033","article-title":"Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic","volume":"61","author":"Herro","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2011.351_bb0080","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/hupa.2000.20370","article-title":"Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis","volume":"31","author":"Izban","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1038\/jid.2011.351_bb0085","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0002-9440(10)65018-3","article-title":"Regulation of CD30 antigen expression and its potential significance for human disease","volume":"156","author":"Kadin","year":"2000","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"10.1038\/jid.2011.351_bb0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.0303-6987.2006.00507.x","article-title":"Pathobiology of CD30+ cutaneous T-cell lymphomas","volume":"33","author":"Kadin","year":"2006","journal-title":"J Cutan Pathol"},{"key":"10.1038\/jid.2011.351_bb0095","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1038\/jid.2011.351_bb0100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1046\/j.1523-1747.2000.00175.x","article-title":"Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression","volume":"115","author":"Levi","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1038\/jid.2011.351_bb0105","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0002-9440(10)64073-4","article-title":"Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray","volume":"158","author":"Li","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1038\/jid.2011.351_bb0110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.1994.12.4.793","article-title":"Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis","volume":"12","author":"Nadali","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1038\/jid.2011.351_bb0115","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1128\/CVI.00047-09","article-title":"Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing","volume":"16","author":"Pavlov","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1038\/jid.2011.351_bb0120","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood-2009-04-217521","article-title":"A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma","volume":"114","author":"Purdue","year":"2009","journal-title":"Blood"},{"key":"10.1038\/jid.2011.351_bb0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.semarthrit.2006.12.007","article-title":"Cytokine production by hepatic anaplastic large-cell lymphoma presenting as a rheumatic syndrome","volume":"37","author":"Siebert","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1038\/jid.2011.351_bb0130","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"10.1038\/jid.2011.351_bb0135","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1038\/jid.2011.351_bb0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1021\/pr100729z","article-title":"Assessment of pre-diagnosis biomarkers of immune activation and inflammation: insights on the etiology of lymphoma","volume":"10","author":"Vendrame","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1038\/jid.2011.351_bb0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.1996.03890250052009","article-title":"Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications","volume":"132","author":"Wasik","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1038\/jid.2011.351_bb0150","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0190-9622(93)70140-O","article-title":"Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment","volume":"28","author":"Willemze","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2011.351_bb0155","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1038\/jid.2011.351_bb0160","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1200\/JCO.1998.16.4.1532","article-title":"Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients","volume":"16","author":"Zinzani","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15356396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15356396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T17:44:10Z","timestamp":1743961450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15356396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0022202X15356396"],"URL":"https:\/\/doi.org\/10.1038\/jid.2011.351","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Soluble CD30, CD25, and IL-6 May Identify Patients with Worse Survival in CD30+ Cutaneous Lymphomas and Early Mycosis Fungoides","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2011.351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}